Quince Therapeutics Halts A-T Drug Development After Phase 3 Trial Miss

Quince Therapeutics ends eDSP development for ataxia-telangiectasia after Phase 3 NEAT trial fails primary endpoints. Stock plunges 91% as company explores strategic options.